Marc Botteman and Ben van Hout from Pharmerit International discuss how to navigate the value challenges of new cancer treatments like CAR-T with payers.
Artificial intelligence is sometimes seen as either a panacea or a destroyer – the fix for all humanity’s problems, or the apocalyptic scourge that will turn on us. Even among less
Oncology is currently a more cutting-edge, dynamic field than it has ever been – as demonstrated at this year’s American Society of Clinical Oncology (ASCO) conference.
